/PRNewswire/ Fuse Oncology, an oncology software solutions company, announces that it has officially closed an oversubscribed Series A. Among the largest.
Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.
The American Society for Clinical Oncology will use their annual meeting to ‘unequivocally recommit ourselves to patients’ whom they say are their ‘most
R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.